Skip to main content
Log in

Opportunities for immune modulation in the spondyloarthropathies with special reference to gut inflammation

  • Published:
Inflammation Research Aims and scope Submit manuscript

Abstract.

The spondyloarthropathies (SpA) are a related group of disorders, characterized primarily by spondylitis, pauci-articular arthritis and enthesitis. The presence of subclinical gut inflammation in patients with SpA ranges from 25 to 75%, depending upon the type of SpA. Several data suggest that the association between gut inflammation and synovitis reflects an etiopathogenetic relationship, and that strategies which interfere with the gut inflammation may also modulate the synovitis. Here we review some standard as well as experimental drugs used in the treatment of patients with inflammatory bowel disease and discuss what is known about their effect on SpA-related locomotor manifestations. For the more experimental drugs, such as cytokines, anti-cytokines and anti-adhesion compounds, clinical trials in patients with SpA are still very scarce.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Additional information

Received 4 February 1999; returned for revision 27 April 1999; accepted by M. J. Parnham 6 October 1999

Rights and permissions

Reprints and permissions

About this article

Cite this article

De Keyser, F., Van Damme, N., De Vos, M. et al. Opportunities for immune modulation in the spondyloarthropathies with special reference to gut inflammation. Inflamm. res. 49, 47–54 (2000). https://doi.org/10.1007/s000110050558

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s000110050558

Navigation